Zoetis Inc.

Zoetis Inc., doing business as Zoetis and operating as a for-profit partnership or limited liability partnership headquartered in Parsippany, New Jersey, supplies veterinary pharmaceuticals, vaccines, diagnostic equipment, and biologics to federal agencies as a prime contractor (100% of awards) on a full-and-open, non-set-aside basis. The company holds a subsidiary in Abaxis, Inc., a manufacturer of diagnostic equipment and reagents. Across the source data spanning 2014 to May 2026, Zoetis has received 97 prime awards valued at $102.1 million in combined potential value, with $25.6 million obligated to date.

Customer concentration is heavily weighted toward the Department of Agriculture. The Department of Agriculture Animal and Plant Health Inspection Service Veterinary Services accounts for 33 awards and $74.2 million in combined potential value (73% of the agency concentration), anchored by a five-year single-award Indefinite Delivery Contract valued at $5.045 million (awarded May 1, 2025, running through May 2030) for Mycobacterium bovis purified protein derivative (PPD) tuberculin in multiple vial sizes to support the National Veterinary Services Laboratories and animal health diagnostic programs. The Department of Agriculture Animal and Plant Health Inspection Service Marketing and Regulatory Programs Business Services holds 3 awards worth $20.3 million, driven by a $1.346 million sole-source Definitive Contract (awarded April 13, 2022, running through August 31, 2028) for one million doses of Classical Swine Fever Virus vaccine for the National Veterinary Stockpile. Three additional APHIS divisions account for $6.7 million. Together, USDA APHIS represents 38 awards and $101.2 million, covering 73% of the award count and approaching 100% of the combined potential value. Secondary customers include the Department of Health and Human Services Indian Health Service (16 awards, $358 thousand, primarily rabies vaccines), the Defense Logistics Agency Troop Support Medical (11 awards, $32 thousand), the National Institutes of Health (6 awards, $34 thousand), and the Department of State Bureau of South and Central Asian Affairs (5 awards, $61 thousand) for Piccolo laboratory analyzers.

Zoetis's capability portfolio spans veterinary pharmaceutical manufacturing (29 awards), in-vitro diagnostic substance manufacturing (18 awards), biological product manufacturing (15 awards), and analytical laboratory instrument manufacturing (9 awards). Representative prime work includes the $626,850 delivery order from USDA Veterinary Services (May 1, 2026) for PPD tuberculin under the ongoing IDC; the $999,963.92 purchase order from USDA Veterinary Services (May 1, 2024) for Zoetis FLU DETECT Avian Influenza Virus Type A Antigen Test Kits; a $35,520 purchase order from the U.S. Fish and Wildlife Service (November 20, 2025) for Telazol chemical immobilization drug supporting the Mexican Wolf Recovery Program; a $99,680 sole-source purchase order from USDA APHIS (April 10, 2026) for BM86 Immunomodulator vials for the Cattle Fever Tick Eradication Program in Texas; and recurrent purchase orders for VETSCAN and HM5 hematology analyzers to the Army Training and Doctrine Command and Army Medical Command ranging from $11,000 to $51,000 per order. The company supplies laboratory diagnostic equipment (Piccolo analyzers, VETSCAN systems) to the Department of State (five orders through the Bureau of South and Central Asian Affairs), the Centers for Disease Control and Prevention, and the National Institute of Allergy and Infectious Diseases.

Activity has declined over the past five years, from 9 awards in 2022 to 4 awards in 2026 year-to-date. Four awards with combined potential value of $1.3 million face ultimate completion within the next twenty-four months, presenting recompete opportunity for competitors and modest recompete risk for Zoetis. The five largest parent vehicles are single-award IDCs with USDA APHIS: IDC 12639520D0026 (7 delivery orders, $3.3 million), IDC AG6395C150051 (7 delivery orders, $3.2 million), IDC 12639525D0024 (2 delivery orders, $1.1 million), IDC AG6395C140106 (2 delivery orders, $497 thousand), and IDC AG6395C140110 (1 delivery order, $2.8 million). All awards carry firm-fixed-price, non-set-aside designations. Zoetis operates as a sole-source supplier on several critical programs (Classical Swine Fever Virus vaccine for the National Veterinary Stockpile, BM86 anti-fever-tick vaccine for the Cattle Fever Tick Eradication Program) where proprietary rights or manufacturing exclusivity limit competition. The company maintains performance locations in Parsippany and Malvern, Pennsylvania, and Ames, Iowa.